This site is intended for healthcare professionals only.

A CGM Roadmap for Personalized Diabetes Care​

Continuous glucose monitoring (CGM) is transforming type 2 diabetes care — but are you confident translating CGM data into clear, individualized treatment decisions for your patients?

Dr. Kristen Flint and leading experts close that confidence gap through practical, case-based insights to help you integrate CGM data with traditional metrics, interpret trends with confidence, and navigate real-world challenges—from discordant data to patient adherence.

Strengthen your ability to deliver truly personalized, data-driven care.
Springer Health+ IME CME-accredited badge

1.0 AMA PRA Category 1 Credits™ available
(Expiry: September 23rd 2027)

Interested in learning more? Listen to Dr. Kristen Flint, as they discuss the goals of this CME program.

Learning Objectives

  • Integrate CGM data with other clinical metrics to guide individualized treatment decisions for patients with type 2 diabetes.
  • Identify and troubleshoot common CGM challenges and patient-reported frustrations.
  • Incorporate CGM trends into longitudinal diabetes management to guide ongoing treatment adjustments.

About the Program

A digital learning experience comprising a suite of CME- accredited activities, including realistic case-based e- learning modules and a real-world patient perspective video, each supported by a downloadable practice aid for reference in clinical practice.

Target Audience

US-based primary care physcians, endocrinologists and the wider diabetes healthcare team

Program Activities

The CGM Challenge: Real-Time Decisions, Real-World Solutions

Doctor connecting continuous glucose monitor with smartphone, to check blood sugar level in real time.
Springer Health+ IME CME-accredited badge

A three-part series of expert-designed, interactive e-learning modules based on realistic clinical patient scenarios.

  • 0.75 AMA PRA Category 1 Credits™ available
  • (Expiry: from October 2027)
  • Three 15-minute modules
Coming October 2026

Understanding the Journey: Addressing Barriers to CGM Adoption in Type 2 Diabetes

Clinician in candid conversation with patient
Springer Health+ IME CME-accredited badge

A patient-physician conversation exploring real-world patient perspectives and shared decision-making insights.

  • 0.25 AMA PRA Category 1 Credits™ available
  • (Expiry: September 23rd 2027)
  • One 15-minute video​
Watch the video

Learning Objectives

  • Integrate CGM data with other clinical metrics to guide individualized treatment decisions for patients with type 2 diabetes.
  • Identify and troubleshoot common CGM challenges and patient-reported frustrations.
  • Incorporate CGM trends into longitudinal diabetes management to guide ongoing treatment adjustments.

About the Program

A digital learning experience comprising a suite of CME- accredited activities, including realistic case-based e- learning modules and a real-world patient perspective video, each supported by a downloadable practice aid for reference in clinical practice.

Target Audience

US-based primary care physcians, endocrinologists and the wider diabetes healthcare team

Meet the Faculty

Headshot of Dr. Kristen Flint

Program Director: Dr. Kristen Flint, MD

Massachusetts General Hospital
Harvard Medical School
Boston, MA, USA

View Biography
Headshot of Prof. Samuel Seidu

Prof. Samuel Seidu,
BSc, MBChB, PGCME, MSc, M.D, FRCP (Edin) FRCGP, FRSM

University of Leicester
Leicester, UK

View Biography
Headshot of Dr. Margaretha Visser

Dr. Margaretha Visser, MD

Leuven, Belgium

View Biography
Headshot of patient Michelle

Patient Contributor:

Michelle
USA

View Biography

Learning Objective

  • Integrate CGM data with other clinical metrics to guide individualized treatment decisions for patients with type 2 diabetes.
  • Identify and troubleshoot common CGM challenges and patient-reported frustrations.
  • Incorporate CGM trends into longitudinal diabetes management to guide ongoing treatment adjustments.

Accreditation

Target Audience

US-based primary care physcians, endocrinologists and the wider diabetes healthcare team

Disclosure of Financial Relationships

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The Springer Health+ IMEplanners and others have nothing to disclose.

All relevant financial relationships have been mitigated.

Funding

This program is made possible thanks to an independent educational grant from Abbott.

Tagged
Headshot of Dr. Kristen Flint

Program Director

Kristen Flint, MD

Massachusetts General Hospital, Harvard Medical School

Boston, MA, USA

Dr. Kristen Flint is an Assistant Professor of Medicine at Harvard Medical School and Associate Physician in Endocrinology at Massachusetts General Hospital. She serves as the Medical Director for Quality for the MGH/BWH Endocrinology Division. She earned her medical degree from Emory University School of Medicine, completed her Internal Medicine residency at Beth Israel Deaconess Medical Center, and completed her fellowship in endocrinology, diabetes and metabolism at Massachusetts General Hospital. Her research focuses on the use of diabetes technologies in the inpatient and primary care settings, and she has particular interest in the implementation and scalability of continuous glucose monitoring in primary care and community health settings.

Disclosures: 
Non-mutual funds stock ownership/Stock options: Doximity, Inc.

David Kerr

Program Director

David Kerr, MBChB, DM, FRCP, FRCPE

Center for Health Systems Research, Sutter Health 
Santa Barbara, CA 
United States

Dr. David Kerr, MBChB, DM, FRCP, FRCPE, a UK trained endocrinologist is currently Senior Investigator in Diabetes and Digital health Equity at the Sutter Health Center for Health Systems Research in Santa Barbara, California (https://www.davidkerrmd.com/).

Dr. Kerr’s recent research has focused on offering wearable digital health technologies, such as continuous glucose monitoring (CGM) devices, to marginalized and historically excluded communities to help them understand the potential value of real-time physiologic data. He has published more than 400 articles, commentaries, and opinion pieces, as well as co-authored the first three books focusing on diabetes and digital health. Dr. Kerr has a Google Scholar i10-index of 173 and an h-index of 54.

Dr. Kerr’s research has also included the use of “food as medicine” for adults with or at-risk of diabetes. He has published the outcomes showing measurable clinical and mental health benefits from the prescription of fresh vegetable produce. Dr. Kerr also has an adjunct position in the department of Computer Science and Electrical Engineering at Rice University in Houston, Texas, is a member of the research committee of the Association of Diabetes Care and Education Specialists, and was recently co-chair of an National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) working group that looked at the impact of innovation on furthering research into the heterogeneity of diabetes.

You can follow Dr. Kerr on “X” at @godiabetesmd. 

Disclosures:  

  • Grant/research support: Abbott Diabetes Care 
Headshot of Prof. Samuel Seidu

Faculty Member

Samuel Seidu, BSc, MBChB, PGCME, MSc, M.D, FRCP (Edin) FRCGP, FRSM

University of Leicester

Leicester, UK

Professor Samuel Seidu is Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK, and serves as Vice-Chair of Primary Care Diabetes Europe. He is a highly ranked scholar, listed as #20 globally in Primary Care and #96 (18th in the UK) in Diabetes over the past five years according to (ScholarGPS® ID: 54268995658494). He is a board member of the UK Primary Care Diabetes Society and co-chairs the Diabetes Delivery Group while also acting as a mentor for diabetes within the Leicester, Leicestershire and Rutland Integrated Care System. In addition, he is Co-Director of the NIHR Applied Research Collaboration (ARC) East Midlands and contributes to academic publishing as an Associate Editor for both the Primary Care Diabetes Journal and Diabetic Medicine.

Disclosures:

Grant/Research support: Dexcom, Lilly, Sanofi
Speakers bureau/Honoraria for non-CME: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Napp, NB Medical, OmniaMed, Roche, SB Communications.
Educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda
Conference registration and subsistence: Abbott, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Takeda
Consultant/Advisory board: Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Janssen, Lilly, MSD, Novo Nordisk, Sanofi, Takeda

Anne Peters

Faculty Member

Samuel Seidu, BSc, MBChB, PGCME, MSc, M.D, FRCP (Edin) FRCGP, FRSM

University of Leicester

Leicester, UK

Professor Samuel Seidu is Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK, and serves as Vice-Chair of Primary Care Diabetes Europe. He is a highly ranked scholar, listed as #20 globally in Primary Care and #96 (18th in the UK) in Diabetes over the past five years according to (ScholarGPS® ID: 54268995658494). He is a board member of the UK Primary Care Diabetes Society and co-chairs the Diabetes Delivery Group while also acting as a mentor for diabetes within the Leicester, Leicestershire and Rutland Integrated Care System. In addition, he is Co-Director of the NIHR Applied Research Collaboration (ARC) East Midlands and contributes to academic publishing as an Associate Editor for both the Primary Care Diabetes Journal and Diabetic Medicine.

Disclosures:

Grant/Research support: Dexcom, Lilly, Sanofi
Speakers bureau/Honoraria for non-CME: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Napp, NB Medical, OmniaMed, Roche, SB Communications.
Educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda
Conference registration and subsistence: Abbott, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Takeda
Consultant/Advisory board: Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Janssen, Lilly, MSD, Novo Nordisk, Sanofi, Takeda

Jennifer L. Sherr

Faculty Member

Jennifer L. Sherr, MD, PhD

Professor of pediatrics
CT, United States

Dr. Jennifer L. Sherr was determined to become a pediatric endocrinologist since the time of her diagnosis with T1D in 1987. While she always wanted to care for those with T1D, her eyes were opened to the meaningful impact that clinical research has. Dr. Sherr has been devoted to clinical research for more than 15 years. She serves as the Medical Director of Pediatric Diabetes and Professor in the Department of Pediatrics at Yale and focuses on methods to improve the lives of all people living with diabetes, including new technologies and therapeutics. 

Disclosures:  

  • Grant/research support: Abbott Diabetes, Dexcom, Insulet, JDRF/Breakthrough T1D, Medtronic, NIG, Provention Bio 
  • Consultant/advisory board: Abbott Diabetes, Cecelia Health, Insulet, Mannkind, Medscape, Medtronic Diabetes, StartUp Health T1D Moonshot, Vertex, Ypsomed 

*Dr. Sherr’s contribution to this publication was made in their individual capacity and not as part of their Yale University duties or responsibilities

Headshot of Dr. Margaretha Visser

Faculty Member

Margaretha Visser, MD

Leuven Belgium

Dr Margaretha Martha Visser (born 14 February 1987, the Netherlands) obtained her master’s degree in Medicine in 2011 at the University of Groningen (RuG).

After a one-year internship at the Internal Medicine department of Medisch Centrum Leeuwarden (MCL), Dr Visser began her Internal Medicine training at the University Medical Center Groningen (UMCG) in 2012, where she graduated as an endocrinologist in December 2018. Fascinated by science, Dr Visser moved to Belgium in January 2019 to pursue a PhD at the Department of Clinical and Experimental Endocrinology at University Hospitals Leuven–KU Leuven. Her PhD focused on the use of continuous glucose monitoring (CGM) in type 1 diabetes, and was supervised by Prof Pieter Gillard and Prof Chantal Mathieu. 

Dr Visser currently works as a staff member in the Department of Endocrinology at University Hospitals Leuven, combining patient care with type 1 diabetes research. She supervises Master’s and PhD students during their theses, and (co-)reviews articles for several peer-reviewed journals. In recent years, Dr Visser has published several articles on CGM in journals such as The Lancet, The Lancet Diabetes & Endocrinology, Nature Metabolism, and Diabetologia.

Disclosures:

Grant/Research support: Vertex

Speakers bureau/Honoraria for non-CME: Novo Nordisk

Anne Peters

Faculty Member

Samuel Seidu, BSc, MBChB, PGCME, MSc, M.D, FRCP (Edin) FRCGP, FRSM

University of Leicester

Leicester, UK

Professor Samuel Seidu is Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK, and serves as Vice-Chair of Primary Care Diabetes Europe. He is a highly ranked scholar, listed as #20 globally in Primary Care and #96 (18th in the UK) in Diabetes over the past five years according to (ScholarGPS® ID: 54268995658494). He is a board member of the UK Primary Care Diabetes Society and co-chairs the Diabetes Delivery Group while also acting as a mentor for diabetes within the Leicester, Leicestershire and Rutland Integrated Care System. In addition, he is Co-Director of the NIHR Applied Research Collaboration (ARC) East Midlands and contributes to academic publishing as an Associate Editor for both the Primary Care Diabetes Journal and Diabetic Medicine.

Disclosures:

Grant/Research support: Dexcom, Lilly, Sanofi
Speakers bureau/Honoraria for non-CME: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Napp, NB Medical, OmniaMed, Roche, SB Communications.
Educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda
Conference registration and subsistence: Abbott, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Takeda
Consultant/Advisory board: Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Janssen, Lilly, MSD, Novo Nordisk, Sanofi, Takeda

Eda Cengiz

Faculty Member

Eda Cengiz, MD

University of California San Francisco (UCSF)
San Francisco, CA
United States

Dr. Eda Cengiz is a professor of pediatrics, pediatric diabetologist by training at the University of California San Francisco (UCSF) School of Medicine, Benioff UCSF professor in children’s health. She is the cross-bay director of the UCSF pediatric diabetes program.

Dr. Cengiz is a pediatric endocrinologist by training, and her research focuses on diabetes technology and insulin action. She has had a chance to work and publish with experts in the filed regarding substance abuse on diabetes management to improve outcomes for people with diabetes who are navigating the complexities of diabetes. 

Disclosures:  

  • Employee/owner: UCSF
  • Grant/research support: Breakthrough T1D, Helmsley, NIH
  • Speakers bureau/honoraria for non-CME: Novo Nordisk
  • Consultant/advisory board: Adocia, Arecor, Eli Lilly, MannKind, Novo Nordisk, Portal Insulin, Tandem, Ypsomed
Headshot of patient Michelle

USA

Michelle

Leuven Belgium

Michelle is a Customer Support executive based in the Northeast, with roughly 20 years spent leading support teams and helping customers get the most out of the products they rely on. At home she has her husband, two kids, and a dog who keeps everyone on their toes. When she’s not working, she’s usually planning the next family trip or finding any excuse to trade the cold for sunny Florida — and she’s rarely without a good book in hand.

Disclosures:

None to disclose

Anne Peters

Faculty Member

Samuel Seidu, BSc, MBChB, PGCME, MSc, M.D, FRCP (Edin) FRCGP, FRSM

University of Leicester

Leicester, UK

Professor Samuel Seidu is Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK, and serves as Vice-Chair of Primary Care Diabetes Europe. He is a highly ranked scholar, listed as #20 globally in Primary Care and #96 (18th in the UK) in Diabetes over the past five years according to (ScholarGPS® ID: 54268995658494). He is a board member of the UK Primary Care Diabetes Society and co-chairs the Diabetes Delivery Group while also acting as a mentor for diabetes within the Leicester, Leicestershire and Rutland Integrated Care System. In addition, he is Co-Director of the NIHR Applied Research Collaboration (ARC) East Midlands and contributes to academic publishing as an Associate Editor for both the Primary Care Diabetes Journal and Diabetic Medicine.

Disclosures:

Grant/Research support: Dexcom, Lilly, Sanofi
Speakers bureau/Honoraria for non-CME: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Napp, NB Medical, OmniaMed, Roche, SB Communications.
Educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda
Conference registration and subsistence: Abbott, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Takeda
Consultant/Advisory board: Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Janssen, Lilly, MSD, Novo Nordisk, Sanofi, Takeda

Close